

## [Salbutamol](#)

Essential medicine status

Section:

[25. Medicines acting on the respiratory tract](#) [25.1. Antiasthmatic and medicines for chronic obstructive pulmonary disease](#)

ATC codes: [R03AC02](#)

Indication

Chronic obstructive pulmonary disease ICD11 code: [CA22](#)

INN

Salbutamol

Medicine type

Chemical agent

List type

Core

Formulations

**Parenteral > General injections > IV:** 500 µg per mL in 1 mL ampoule (as sulfate) ; 500 µg per mL in 5 mL ampoule (as sulfate)

**Respiratory > Inhalation > solution:** 100 µg per actuation in pressurized metered dose inhaler (as sulfate) ; 2.5 mg per 2.5 mL in 2.5 mL ampoule (as sulfate) for use in nebulizers ; 5 mg per 2.5 mL in 2.5 mL ampoule (as sulfate) for use in nebulizers ; 5 mg per mL in multi-dose bottle (as sulfate) for use in nebulizers

EML status history

First added in 2003 ([TRS 920](#))

Changed in 2009 ([TRS 958](#))

Changed in 2011 ([TRS 965](#))

Changed in 2021 ([TRS 1035](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Adolescents and adults

Therapeutic alternatives

[terbutaline](#) (ATC codes: [R03CC03](#))

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Salbutamol](#)

DrugBank

[Salbutamol](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations of essential medicines for children, the Expert Committee recommended the following changes to the listing of salbutamol on the EML and EMLc: - update the listing description of inhalation delivery systems for consistency across the Model Lists and to better reflect product characteristics. - amend the listed strength of salbutamol injection from 50 micrograms/mL in 5 mL ampoule to 500 micrograms/mL in 1 mL and 5 mL ampoules.